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Abstract
Vitamin D (VD) is a molecule that can be synthesized directly in the humans’ 
body or enter the organism with food in the form of inactive precursors. To exert 
its biological action, VD undergoes two-stage hydroxylation (at the 25th and 1st 
position) catalyzed by cytochromes P450, the presence of which has already been 
shown in almost all tissues of the human body. The product of hydroxylation is 
hormone-active form of vitamin D–1,25(OH)2D. 1,25(OH)2D binds to specific 
vitamin D receptor (VDR) and regulates the expression of genes involved in bone 
remodeling (classical function) and genes that control immune response, hor-
mone secretion, cell proliferation, and differentiation (nonclassical functions). 
VD deficiency is prevalent around the globe and may be one of the key factors for 
diabetes development. The direct association between vitamin D deficiency and 
type 1 (T1D) and type 2 (T2D) diabetes has been proven. Detection of VDR in 
pancreas and adipose tissue, skeletal muscles, and immune cells allowed implying 
the antidiabetic role of vitamin D by enhancing insulin synthesis and exocytosis, 
increasing the expression of the insulin receptor, and modulating immune cells’ 
functions. This chapter summarizes data about relationship between VD insuffi-
ciency/deficiency and development of T1D and T2D, and their complications.
Keywords: cholecalciferol, vitamin D deficiency, vitamin D receptor, CYP27B1 
(1α-hydroxylase), type 1 diabetes mellitus, type 2 diabetes mellitus, immune response
1. Introduction
Vitamin D (VD) is a unique bioregulatory molecule as it can be synthesized 
in the skin in addition to its dietary sources. VD in its metabolically active form, 
1,25(OH)2D (calcitriol), is a secosteroid hormone produced after hepatic (at carbon 
atom 25) and, not exclusively, kidney (at carbon atom 1) hydroxylations. The well-
studied function of VD is associated with its ability to regulate metabolic processes 
in skeletal tissue by affecting mineralization, maintaining a balance between the 
formation and resorption of bone tissue, and thereby contributing to the preven-
tion of osteoporosis and the occurrence of fractures. In addition to being involved 
in calcium-phosphate metabolism, the variety of physiological effects of VD also 
extends to extra-skeletal tissues, since the vast majority of their species possesses 
vitamin D receptor (VDR). Furthermore, most of these tissues also express the 
cytochrome P450 enzyme, CYP27B1, responsible for converting 25-hydroxyvi-
tamin D (25OHD), the main circulating metabolite of VD, to hormonally active 
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form–1,25(OH)2D. 1,25(OH)2D through VDR controls the expression of both those 
genes that participate in mineral homeostasis and bone remodeling, and genes 
(about 500) that participate in various cellular pathways that affect physiological 
and cellular mechanisms, such as immunomodulation, hormone secretion, inhibi-
tion of cell proliferation, and induction of cell differentiation.
Recent epidemiological studies have indicated the association between VD 
deficiency and both type 1 (T1D) and type 2 (T2D) diabetes mellitus. Moreover, 
impaired glucose tolerance and diabetes have been shown to ameliorate in 
VD-deficient individuals after VD supplementation. Vitamin D deficiency, which 
may be a key factor for diabetes development, is prevalent around the globe, with an 
estimated one billion people being vitamin D deficient. The role of VD in diabetes 
became clearer after the discovery of VDR in the pancreas, adipose tissue, skeletal 
muscle cells, and immune cells, which indicates a regulatory effect of VD on glucose 
homeostasis. Vitamin D can directly enhance insulin synthesis and its release 
from pancreatic β-cells as well as increase the expression of the insulin receptor in 
peripheral tissues. It can also indirectly exert an antidiabetic effect by acting on 
cells of the immune system that secrete pro-inflammatory cytokines as mediators 
affecting weight gain, systemic inflammation (contributes to insulin resistance), 
and autoimmune-mediated destruction of pancreatic β-cells. These findings sug-
gested that VD deficiency probably has a causal relationship with diabetes mellitus. 
Some studies have also reported that VD deficiency was not the cause, but the result 
of diabetes. Regardless of whether this deficiency is one of the causes of diabetes or 
its consequence, it is obvious that low levels of VD are closely associated with poor 
regulation of diabetes and its complications; however, the extent of this relationship 
and its clinical relevance are not well established.
The aim of the present chapter is to summarize the latest evidence linking VD 
insufficiency/deficiency with the development of T1D and T2D and their compli-
cations. We also analyzed different intervention studies with VD supplements to 
determine their influence on glucose metabolism and delineated the underlying 
mechanisms. Previous reviews on the role of VD in diabetes mellitus have been 
published in recent years. Here, priority was given to the most recent and convinc-
ing available evidence.
2. Role of vitamin D in immune regulation and inflammatory responses
The first data concerning the potential role for VD and its active metabolite 
1,25(OH)2D in modulating the immune response were obtained as a result of the 
treatment of tuberculosis and leprosy caused by mycobacteria [1]. However, the 
mechanisms underlying these observations have been clarified more recently with 
several important discoveries: (1) the upregulation of CYP27B1 and VDR expres-
sion in activated human inflammatory cells, thus providing their ability both to 
produce 1,25(OH)2D in the site of inflammation and to respond to this hormon-
ally active metabolite; and (2) the participation of 1,25(OH)2D in modulating the 
multiple pathways of the innate and adaptive immune system. The influence of 
1,25(OH)2D on the different cell types of these immune system segments is outlined 
in Figure 1.
Innate immune response involves the activation of Toll-like receptors in mono-
cytes/macrophages as well as in a number of cells such as placenta trophoblasts, 
keratinocytes, and epithelial, intestinal, lung, and corneal cells, representing 
first-barrier defenses. VD affects innate immunity through its stimulatory action 
on the synthesis of defensin β2 and cathelicidin antimicrobial peptide (CAMP) 
upon Toll-like receptors’ activation. These low molecular weight host defense 
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antimicrobial peptides demonstrate a broad spectrum of activity against bacteria, 
viruses, and fungi in the immune cells and are also synthesized in a variety of other 
cell types [1]. CAMP is known to be a direct transcriptional target of VD, which is 
induced by binding of 1,25(OH)2D-VDR/retinoid X receptor (RXR) complex to 
the VD response elements (VDRE) in the gene promoter [2]. VD can also modulate 
innate immune system by increasing chemotaxis, autophagy, and phagolysosomal 
fusion of phagocytic cells. Notably, VD’s action on macrophages was established to 
be modulated by interleukins. In particular, VD increases the antimicrobial activity 
of macrophages formed after the IL-15 stimulus, while phagocytic macrophages do 
Figure 1. 
Vitamin D in immune modulation. 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D; 
IFN-γ, interferon-γ; ILs, interleukins; TGF-β, transforming growth factor β; Th1, type 1 T helper; Th2, type 2 
T helper; Th17, type 17 T helper; TNF-α, tumor necrosis factor-α; Treg, regulatory T cells.
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not respond to vitamin D after the IL-10 stimulus, regardless of their high phago-
cytic activity [1, 3].
Vitamin D shows an inhibitory action on the adaptive immune system, the 
responses of which include the ability of T and B lymphocytes to produce cytokines 
and immunoglobulins, respectively, to specifically combat antigens presented to 
them by macrophages and dendritic cells (DCs). Experimental studies have yielded 
encouraging results on the immunomodulatory effect of calcitriol on T helper 
(Th) cells. In particular, 1,25(OH)2D was shown to suppress the immune responses 
mediated by Th1 cells capable of producing such pro-inflammatory cytokines as 
IL-2, IL-6, interferon γ (IFN-γ), and tumor necrosis factor-α (TNF-α) [4]. The 
lack of IFN-γ prevents further antigen presentation to T lymphocytes and their 
recruitment, while lower IL-2 production impedes T lymphocyte proliferation 
and differentiation. It has been recently demonstrated that calcitriol also increases 
formation and activity of CD4+/CD25+ regulatory T cells (Treg) as seen by elevated 
FoxP3 and IL-10 expression [5]. Increased levels of IL-10 as well as other cytokines 
with anti-inflammatory properties, induced by calcitriol, block Th1 differentiation, 
thus shifting the balance from Th1 to Th2 cell phenotype [6]. Many of the effects of 
VD on Th1 cells, which were previously considered to be implicated in the patho-
genesis of several autoimmune diseases, can now be attributable, at least in part, 
to the inhibitory action of 1,25(OH)2D on the formation and activity of Th17 cells, 
producing IL-17 [5]. The overall impact of VD on Th cells is related to the suppres-
sion of antigen-presenting cells (APCs) of the innate immune system, including 
the most potent dendritic cells. This modulatory effect of 1,25(OH)2D induces a 
“tolerogenic state” associated with the differentiation of Treg cells, autoreactive T 
cell apoptosis, reduced production of inflammatory cytokines, and increased levels 
of the anti-inflammatory cytokines.
Chromatin immunoprecipitation assay revealed VDR binding to a VDRE in the 
proximal area of IL-10 promoter in antibody-producing cells of the immune system, 
or B-cells [7]. 1,25(OH)2D blocked the proliferation of activated B-cells and stimulated 
their apoptosis. It also inhibited maturation of activated B-cells into plasma cells and 
memory cells that is consistent with the inhibitory action of VD on the secretion of 
IgM and IgG [8]. Several observational trials showed an inverse relationship between 
serum IgE and 25OHD levels, while others indicated a positive correlation [9].
Due to the ability of VD to suppress the adaptive immune system, the role of 
VD deficiency and supplementation in inflammatory and autoimmune diseases 
acquires more comprehensive support. In a number of animal models, including 
autoimmune diabetes, inflammatory arthritis, experimental allergic encephalitis, 
and different mouse models of enterocolitis, calcitriol prevented the initiation and 
reduced the disease progression. However, despite strong experimental evidence, 
human studies are less convincing to prove a role for VD in the modulation of adap-
tive immune system of individuals affected by autoimmune diseases. In this respect, 
some trials have confirmed beneficial effect of VD on different inflammatory 
disease progression, inflammatory markers, and T cell subsets, whereas others have 
not shown any promising result [10, 11].
3.  Vitamin D in maintaining pancreatic β-cell function and regulating 
insulin sensitivity
As demonstrated in the previous section, VD is one of the key players in the 
control of immune homeostasis, and here, we will examine in more detail the 
molecular mechanisms, showing how inadequate VD status and inflammation can 
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contribute to pancreatic β-cell dysfunction and the formation of insulin resistance 
(IR). Comprehensive results of experimental and clinical studies have shown that 
vitamin D is a potential regulator of pancreatic β-cell survival, Ca2+ levels, insulin 
secretion, and insulin signaling (Figure 2).
Vitamin D plays an immunomodulatory role in preventing pancreatic β-cell 
dysfunction and death, via VDR, which is expressed along with Cyp27B1 in APCs, 
activated T cells, and islet pancreatic β-cells [12]. These effects have been demon-
strated in many studies of nonobese diabetic mice using 1,25(OH)2D or analogs. 
Conversely, 1,25(OH)2D-deficient mice showed a tendency to develop more aggres-
sive form of T1D, if the deficiency is present at an early age. The bioactive form of 
VD protects against the development of insulitis in the pancreas or reduces their 
Figure 2. 
Mechanisms of glucose homeostasis deregulation related to vitamin D deficiency status. Cyp27B1, 




severity through a dual mechanism of action on both pancreatic β-cells and immune 
cells [13].
In pancreatic islets, 1,25(OH)2D decreases, as was shown in in vitro and in vivo 
experiments, the expression of pro-inflammatory cytokines (e.g., IL-6), which are 
involved in the pathogenesis of T1D, making β-cells less chemoattractive and less 
prone to inflammation [14]. This leads to a decrease in T-cell recruitment and infil-
tration, an increase in regulatory cells, and a delay in the autoimmune process. In 
addition, 1,25(OH)2D reduces the expression of MHC class I, leading to a decrease 
in the vulnerability of islet β-cells to the action of cytotoxic T lymphocytes [13, 14].
At the level of the immune system, 1,25(OH)2D inhibits the differentiation and 
maturation of DCs and promotes their apoptosis, preventing them from becom-
ing APCs, which is the first step in initiating an immune response. It has also been 
shown that 1,25(OH)2D restores suppressor cells, reduces cytokine formation by 
Th1 cells responsible for β-cell death, and shifts the immune response toward Th2 
cell activation, leading to more benign inflammatory response in pancreatic islets. 
1,25(OH)2D suppresses the formation of IL-6, a direct stimulator of Th17 cells 
involved in the pathogenesis of various autoimmune diseases, including T1D [15]. 
On the other hand, 1,25(OH)2D exerts an antiapoptotic effect on cytokine-induced 
apoptosis of pancreatic β-cells. It induces and maintains high protein levels of the 
A20 (anti-inflammatory protein; inhibits NF-κB signaling), leading to a decrease 
in nitric monoxide (NO) levels. In fact, NO is able to directly induce β-cell dysfunc-
tion and death, or indirectly may affect β-cell function through the induction of 
Fas expression. Fas is a transmembrane cell surface receptor and a member of the 
TNF receptor superfamily. Activation of these receptors occurs under the influ-
ence of inflammatory cytokines secreted by mononuclear cells that infiltrate islet 
cells. Reduction of the NO level leads to inhibition of all the above mechanisms 
and allows realizing cytoprotective effect on islet β-cells. The ability of 1,25(OH)2D 
to counteract the cytokine-induced expression of Fas in human pancreatic islets 
at both mRNA and protein levels, modulating the cell death signal cascades and 
preventing β-cell apoptosis, was established [16].
Several trials have reported that VD deficiency caused impairment of glucose-
mediated secretion of insulin in rat pancreatic β-cells, which was restored after VD 
supplementation. However, the results of clinical studies are not unambiguous as 
VD adequacy was not always associated with the improvement of insulin secretion. 
This stimulatory effect of VD is important for the prevention of T2D and may have 
different explanations. The bioactive form of VD is able to induce insulin secretion 
through direct binding of VDR-RXR complex to VDRE previously identified in the 
promoter of insulin gene in pancreatic β-cells [17]. In accordance with this finding, 
mice with a lack of functional VDR showed impaired insulin secretion after stimula-
tion with glucose [18]. It is noteworthy that VDRE can stimulate not only the tran-
scription of the insulin gene but also many other genes involved in the organization 
of the cytoskeleton, cell growth, differentiation, and survival of pancreatic β-cells.
In addition to genomic effects, rapid nongenomic mechanism of VD action 
appears to be involved in depolarization-stimulated insulin exocytosis by regulating 
intracellular Ca2+. This effect of calcitriol is realized through a membrane VDR-
mediated increase in the synthesis of inositol trisphosphate and phospholipase C 
that promotes the release of Ca2+ from endoplasmic reticulum and diacylglycerol-
mediated PKC activation. In turn, activated PKC phosphorylates the ATP-dependent 
K+ channels and L-type voltage-dependent Ca2+ channels. Ultimately, these effects 
lead to depolarization of the cytoplasmic membrane and the opening of Ca2+ L-type 
and T-type channels that increase intracellular Ca2+ level and, accordingly, insulin 
secretion [19]. Activation of PKA signaling pathways by calcitriol, apparently, is also 
involved in the regulation of L-type voltage-dependent Ca2+ channels.
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It has been suggested that increased intracellular Ca2+ induced by VD may 
enhance the expression of cAMP-responsive element-binding protein (CREB), 
responsible for maintaining efficient transcription of insulin gene and insulin 
exocytosis, as well as for the glucose sensing and pancreatic β-cell survival [20]. 
Increased expression of proteins involved in providing low resting Ca2+ level, such 
as calcium-binding proteins (parvalbumin, calbindin-D28k, and calbindin-D9k), 
plasma membrane Ca2+-ATPase, and Na+/Ca2+-exchanger, can be another mecha-
nism by which vitamin D affects insulin secretion [21]. Furthermore, preclinical 
studies have shown that VD improves β-cell function by reducing the excess activity 
of the renin-angiotensin-aldosterone system [22].
Optimal intracellular levels of Ca2+ are essential not only for the proper func-
tion of pancreatic β-cells but also for insulin-responsive tissues, including liver, 
adipose tissue, and skeletal muscles. Impaired regulation of extracellular and 
intracellular Ca2+ concentrations due to abnormal transduction of insulin signaling 
in target tissues may evoke dephosphorylation and decreased activity of glucose 
transporter-4 (GLUT-4), leading to a phenomenon known as peripheral insulin 
resistance. The results of several studies confirmed that VD deficiency is involved 
in the onset of IR. Moreover, an adequate VD level was shown to improve insulin 
resistance associated with T2D [23]. In addition to the effect of calcitriol on insulin 
sensitivity related to regulation of extracellular Ca2+ concentration and its influx 
into cells through cell membranes, the active metabolite of VD seems to be an 
inducer of insulin receptor expression, which in turn improves insulin sensitivity 
[23]. Another mechanism underlying the beneficial effects of calcitriol on insulin 
sensitivity is related to activation of the peroxisome proliferator-activated recep-
tor delta (PPARδ) [22]. Activated PPARδ, as a transcription factor, reduces fatty 
acids-evoked IR in adipose tissue and skeletal muscles. A secondary elevation of 
parathyroid hormone (PTH) in response to VD deficiency can also increase the 
concentration of intracellular Ca2+ in insulin-sensitive tissues and exacerbate IR 
by decreasing the number of GLUT1 and GLUT4 in the cell membranes of adipose 
tissue, liver, and muscle, thereby reducing glucose uptake [24].
An important endocrine and metabolic organ, playing a crucial role in glucose 
homeostasis and energy balance, is adipose tissue. This tissue is also the major site 
of VD storage in an organism that can sequestrate a fat-soluble prehormone and 
significantly decrease its level in blood circulation. It was found that VD exerts an 
important effect on the expression of genes implicated in promoting adipogenesis 
and adipose tissue remodeling. VDR is expressed in adipocytes in early stages of 
adipogenesis and mediates inhibitory effect of calcitriol on adipocyte differentia-
tion through Wnt/β-catenin and mitogen-activated protein kinase (MAPK) signal-
ing pathways [25]. Suppressive action of 1,25(OH)2D on transcription factors, such 
as PPARγ and CAAT/enhancer-binding protein α (C/EBPα), alters the expression 
of numerous genes involved in lipolysis, lipogenesis, secretion of adipokines, 
insulin sensitivity (via GLUT4 expression), and transfer of fatty acids across the 
membrane [26].
The association between obesity, IR, and VD deficiency is a subject of intense 
research. A characteristic feature of hypertrophic enlargement of adipose tissue 
is elevated release of pro-inflammatory cytokines (TNF-α, IL-6, IL-8, MCP1, and 
resistin) by adipose-resident macrophages and activated T lymphocytes, whereas 
secretion of adiponectin, an anti-inflammatory and insulin-sensitizing bioregula-
tory molecule, by adipocytes is reduced [27]. Thus, one of the harmful conse-
quences of obesity is impaired secretion of adipokines and systemic inflammation, 
which coexists with IR and favors the development of T2D as a key contributing 
factor. VD is known to protect against IR associated with inflammation by modu-
lating the function of immune cells and secretion of adipokines (adiponectin and 
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leptin). It has been reported in numerous trials using animal models and in several 
human observational studies that higher VD levels are accompanied by lower 
inflammatory markers including TNF-α, IL-6, and C-reactive protein in healthy 
persons, and in those with inflammation-associated diseases, such as arterioscle-
rosis, inflammatory polyarthritis, and diabetes [28]. As for adipokines, positive 
correlation was shown between VD and adiponectin, and inverse correlation 
between VD and leptin [29]. Finally, VD by targeting mitochondrial respiratory 
functions through multiple mechanisms also attenuates oxidative stress and exerts 
key beneficial effects on controlling inflammation, impaired energy metabolism, 
and cell apoptosis. However, this topic is beyond the scope of this chapter. Vitamin 
D functions associated with the regulation of β-cell function and insulin sensitivity 
are summarized in Figure 2.
4. Vitamin D deficiency and type 1 diabetes mellitus
Type 1 diabetes mellitus is an autoimmune disorder caused by the progressive 
T-cell-mediated destruction of insulin-producing β-cells in the pancreas. T1D is 
commonly diagnosed in childhood and young adults, who are ultimately at risk 
of the long-term complications of diabetes [30]. This autoimmune condition is 
characterized by a state of hypoinsulinaemia and insulin-like growth factor (IGF-1) 
deficiency. T1D is triggered by a combination of both genetic and environmental 
factors including viral infections, dietary antigens, disruption in the gut microbiota, 
and VD deficiency [31].
Data regarding the presence of VDR in immune cells (B- and T-lymphocytes) 
and their ability to produce hormonally active form of VD locally, which acts on 
immune cells in auto-/paracrine manner, give the evidence that VD is an important 
regulator of multiple pathways of innate and adaptive immunity. In addition to 
immune-modulating properties, VD seems to play a role in the regulation of insulin 
secretion from β-cells. Respectively, VD insufficiency/deficiency is frequently 
reported to be associated with immunological disorders such as T1D, multiple 
sclerosis, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, 
inflammatory bowel disease, hepatitis, asthma, and respiratory infections [32]. 
The link between the state of VD deficiency and T1D is a latter-day considerable 
area of interest; however, the presence of the clear association and especially causal 
relationship between low VD status and the occurrence of T1D still remains disput-
able and controversial.
Most of the international epidemiological and clinical studies have provided 
evidence to this causal relationship primarily in children. It has been reported 
previously that low 25OHD concentrations are fairly prevalent in the UK children 
with T1D [33]. Moreover, it has been shown that genetic factors affecting the VD 
metabolic pathway during the pregnancy can be related to the development of 
T1D. Another study emphasized that the fetal environment, including maternal 
VD metabolism, may be one of those factors that can lead to the early onset of T1D 
in Finnish children [34]. The study of VD level and its associated factors in Korean 
youth with T1D showed that serum 25OHD and 1,25(OH)2D levels were lower in 
T1D cases than in healthy controls [35]. Nevertheless, in other cross-sectional study 
of subjects in Seoul National University Children’s Hospital, there was no signifi-
cant difference in the frequency of VD deficiency or serum 25OHD level between 
healthy and pediatric T1D patients [36].
There is much less data available regarding adult patients with T1D. It has 
been observed that the serum concentration of VD is negatively associated with 
IR in adult diabetic patients recruited in Poland [37]. In Algerian population, the 
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link between VD deficiency and an increased risk of T1D was also found [38]. In 
contrast, there was no difference reported between Turkish adult T1D patients and 
healthy controls according to their vitamin D levels [39]. The exact reason for these 
conflicting results is unclear; thus, we can assume that the interplay of genetic, 
nutritional, and environmental factors seems to affect the circulating level of VD 
status marker (25OHD) in adult T1D patients.
The cellular and molecular mechanisms underlying the VD deficiency in 
patients with TID deserve further thorough and comprehensive study. More 
recently, in addition to measuring the level of 25OHD, increased attention has been 
paid to new experimental directions, in particular, the investigation of the state 
of the VD auto-/paracrine system, including the following key components: VDR, 
CYP27B1, and 24-hydroxylase (CYP24A1).
Different genetic factors including mutations are known to modify serum 
25OHD concentration. Several single nucleotide polymorphisms (SNPs) in the 
metabolic pathway of VD contribute as the genetic component to VD status. There 
is a set of studies dedicated to the associations between T1D and mutations related 
to VD metabolism genes such as VD-binding protein (VDBP), VDR [34, 40, 41], 
and CYP24A1. Moreover, polymorphisms in CYP2R1 gene encoding the enzyme 
involved in 25-hydroxylation of VD were also shown to be associated with a higher 
risk of T1D. Thus, polymorphisms in VD metabolism genes may contribute to 
susceptibility to T1D in Korean children [35]. Another study linked T-cell prolifera-
tion with VDBP level and reported higher levels and frequencies of serum anti-DBP 
antibodies in patients with T1D vs. healthy controls. This study postulated that 
VDBP, which was shown to be expressed in cells of pancreatic islets, can act as an 
autoantigen in T1D [42]. Furthermore, it has been reported that lower maternal 
third trimester VDBP levels and cord blood VDBP levels have been associated 
with a higher risk of T1D in offspring [43, 44]. At the same time, there is a lack of 
studies related to the investigation of the role of CYP27B1 in immune cells, such as 
monocytes, macrophages, and T-cells, which could shed light on the involvement 
of impaired VD metabolism in the pathogenesis and/or prevention of T1D. Thus, 
as VD biosynthesis and its signaling are regulated by genes encoding the VDR and 
enzymes of VD activation/catabolism, their polymorphisms may significantly alter 
the bioavailability and specific effects of VD metabolites.
Taken together, these data point to a role of VD deficiency in increasing the risk 
of T1D progression that provides the basis for further prospective studies on devel-
oping guidelines for vitamin D intake to prevent VD deficiency in patients with T1D 
and to treat this disease.
Since VD is considered a potential diabetes risk modifier, more studies appear 
to evaluate the role of vitamin D as an adjunctive therapy in improving glycemic 
control. The recent international study revealed that the majority of participants 
in Finland, Germany, and Sweden (97–99%) and 50% in the US receiving VD 
supplements during infancy demonstrated a reduced risk of T1D [45]. In another 
clinical trial, patients with T1D and low 25OHD concentrations were treated with 
different doses of cholecalciferol once daily for 3 months depending on their VD 
status, and as a result, it has been established that cholecalciferol can potentially 
improve the glycemic control [33]. Recent studies have shown favorable changes 
in HbA1c, C-peptide, insulin dose, and insulin sensitivity in VD-supplemented 
patients; therefore, cholecalciferol is increasingly attracting attention as a potential 
additional therapy in patients with T1D. In a double-blinded randomized controlled 
trial, which included Indian children with T1D, oral VD supplementation was used 
for six months in addition to insulin therapy. It has been proven that VD treatment 
may serve as an adjuvant to insulin therapy for children with T1D due to its effect 
on augmenting residual β-cell function and improving insulin secretion [46]. Some 
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representative studies on mechanisms of VD action in T1D described a beneficial 
effect of its supplementation on regulatory T-cells, with an increase in their per-
centage [47], suppressive capacity [48], and reduced progression to undetectable 
C-peptide.
However, some other studies have not demonstrated a beneficial effect of VD 
supplementation in preventing/improving the course of T1D or its complications. 
The prospective Environmental Determinants of Diabetes in the Young (TEDDY) 
Study demonstrated no benefit of maternal VD supplementation during pregnancy 
on the risk of islet autoimmunity in the offspring [49]. According to the review 
[32], there was no beneficial impact of VD supplementation on β-cell function, 
HbA1c levels, or insulin requirement.
The reason for these conflicting results is unclear. Nevertheless, we can presume 
the presence of a plethora of factors that may affect the results. Differences in 
study design, seasonal differences, stages in the progression of diabetes, ethnic 
origin of the populations, age and gender of patients may contribute. Therefore, 
further randomized controlled trials with a larger sample of patients are needed to 
gain more insight into the relationship between VD and T1D and to investigate VD 
replacement in preventing T1D.
The life expectancy of T1D patients has increased substantially during the last 
decades due to the availability of exogenous insulin, though it is still shorter than 
that of healthy people and associated with the development of chronic complica-
tions. Traditionally, the diabetic complications have been classified as either 
microvascular (retinopathy, nephropathy, and neuropathy) or macrovascular 
(cardiovascular disease, cerebrovascular accidents, and peripheral vascular dis-
ease). Although intensive glycemic control significantly reduced the incidence of 
microvascular and macrovascular manifestations, the majority of patients with T1D 
are still developing these outcomes. Most clinical trials related to the influence of 
VD supplementation on diabetes-associated complications have been performed in 
patients with T2D. To date, a limited number of experimental and clinical trials are 
available regarding the effect of VD on complications associated with T1D.
Diabetic ketoacidosis, which is the most dangerous and life-threatening com-
plication of mainly T1D that results from insulin deficiency or excess of adrenaline 
or cortisol, is found to be associated with low VD level. VD is known to protect 
against viral and bacterial infections, which were shown to be triggering factors for 
diabetic ketoacidosis [50]; as a result, VD supplementation can become an integral 
part of diabetic ketoacidosis prevention and management. Nephropathy is another 
well-characterized complication of T1D, resulting in proteinuria and urinary loss 
of micronutrients. It has been previously found that the dietary supplements may 
modulate VD balance, attenuate polyuria, proteinuria, and renal hypertrophy 
in experimental T1D [51]. In addition, it has been reported that VD may reduce 
diabetic nephropathy not only by improving blood glucose and insulin levels but 
also by modulating hexosamine pathways in kidneys [52]. More recently, it has 
been shown that 1,25(OH)2D may improve diabetic cardiomyopathy in T1D rats by 
modulating autophagy through the β-catenin/TCF4/GSK-3β and mTOR pathway 
[53]. Several studies have also demonstrated an association between low VD levels 
and diabetic peripheral neuropathy. Since VD is a well-known neurosteroid, a 
possible beneficial effect of its supplementation on preventing diabetic peripheral 
neuropathy can be assumed; nevertheless, further studies are needed.
Type 1 diabetes mellitus is a secondary cause of osteoporosis, characterized 
by reduced bone mass and disturbed bone microarchitecture. Patients with T1D 
have increased fracture risk that may be determined by the low 25OHD levels. 
Diabetic retinopathy, advanced cortical cataracts, and diabetic neuropathy are 
the risk factors for increased number of falls and, as a result, fracture because of 
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visual impairment and alterations in balance [54]. Replacement of VD along with 
calcium has been found to improve the bone mineral density in children with T1D; 
therefore, an adequate calcium level and VD supplementation are important for the 
prevention of T1D-associated osteoporosis [55].
According to available experimental and clinical data, new recommendations 
for T1M patients have been developed including obligatory assessment of serum 
25OHD level and prescription of personalized doses of vitamin D in order to avoid 
the development of T1M complications or at least detain its progression.
5. Vitamin D deficiency and type 2 diabetes mellitus
Type 2 diabetes mellitus, formerly known as adult-onset diabetes, is a complex 
chronic metabolic disorder that has become one of the most serious public health-
care problems worldwide. According to the data of the World Health Organization, 
2.2 million people died from diabetes in 2012 and 1.6 million people died in 2015, 
and diabetes is expected to be the 7th cause of death by 2030. The incidence of 
T2D is estimated to account for 90% of all diabetes cases. T2D is characterized by 
dysfunction of pancreatic β-cell, systemic inflammation, and hyperglycemia due to 
insufficient insulin production, insulin action, or both [56]. A high diabetes-associ-
ated concentration of glucose in the blood over an extended period can cause heart 
disease, diabetic retinopathy, renal failure, poor blood circulation in the limbs, and, 
as a consequence, amputations.
T2D mainly develops as a result of the summation of genetic, environmental, 
and other risk factors [57]. To date, an increased risk of developing T2D in monozy-
gotic twins with a statistical reliability of about 96% has been convincingly shown. 
Moreover, the risk of developing this disease in children from diabetic parents is 
40% higher than in the offspring of healthy parents. T2D is now regarded as an 
endocrine-metabolic disease of a polygenic nature. About 75 loci have already been 
identified, damage to the sequences of which can be directly associated with the risk 
of developing T2D. These genes encode proteins with very different functions, such 
as ion channels (KCNJ11; potassium inwardly rectifying channel, subfamily J, and 
member 11), various transcription factors (TCF7L2, transcription factor 7-like 2), 
receptors (IRS1, insulin receptor substrate 1; MTNR1B, melatonin-receptor gene; 
and PPARγ2), growth factors (IGF2BP2, insulin-like growth factor two binding 
protein 2), as well as CDKN2A (cyclin-dependent kinase inhibitor 2A), HHEX 
(hematopoietically expressed homeobox protein), and FTO (fat mass and obesity-
associated protein) [58–60].
Despite the growing body of data on the relationship between the risk of devel-
oping T2D and certain genes, improper food behavior and the sedentary lifestyle 
are still considered the key reasons for the development of the disease. In a number 
of experimental and clinical studies, VD has been shown to exhibit various non-
skeletal properties that significantly regulate glucose metabolism. Furthermore, 
human studies have clearly revealed an inverse association between vitamin D 
status and the prevalence of T2D. It was found in numerous observational studies 
that the concentration of 25OHD negatively correlates with deteriorated glucose 
homeostasis, IR, and impaired β-cell function [61]. Low blood serum 25OHD levels 
were associated with the negative changes in a number of metabolic parameters, 
indicative of IR, including BMI (body mass index), HOMA-IR (homeostatic model 
assessment for IR), TG (triglycerides), HDL (high-density lipoproteins), LDL 
(low-density lipoproteins), TC (total cholesterol), and HbA1c [62]. More recently, 
large-scale epidemiological studies have been carried out as for the dependence of 
the risk of T2D developing on the availability of VD. VD deficiency has been shown 
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to be widespread in both men and women in different age groups among Saudi 
citizens, and this was accompanied by hyperglycemia in 90 percent of patients [63]. 
T2D patients studied in India also showed VD deficiency of varying severity in 77% 
of subjects [64]. The association between a low serum of 25OHD concentration and 
an increased risk of developing T2D can be partially explained by an increase in fat 
mass. A study of serum 25OHD in patients with T2D from the urban area of Cairo 
with limited exposure to the sun and overdressing habit revealed a decrease of its 
level by 13% compared with the control. Depleted level of the prohormone has been 
found to be related to a higher risk of insulin resistance [65].
However, as it turned out, not all studies confirmed a decrease in VD contents in 
patients with T2D. Using the method of high-performance liquid chromatography 
in tandem with mass spectrometry, significantly higher levels of VD were demon-
strated in patients with T1D and T2D in comparison with the control group [66].
Overall, most of the data presented here suggest a pivotal role of VD in the 
regulation of insulin secretion and confirm that the decreased insulin sensitivity at 
target organs may be attributable to VD inadequacy [67]. The relationship between 
VD deficiency and IR could be realized at the level of modulation of immune 
processes and inflammation, since VD deficiency is associated with an increase in 
inflammatory markers. In addition, genetic polymorphisms of VD-related genes 
such as VDR, CYP2R1, and CYP27B1 may predispose to impaired glycemic control 
and T2D [68].
As we mentioned earlier, VD mediates its biological activity through VDR, 
which belongs to the family of steroid hormone receptors. Many VDR gene SNPs 
have been identified to be related to T2D, in particular to insulin synthesis and 
release [69]. The most reported VDR SNPs associated with diabetes are Fok1, Bsm1, 
Taq1, and Apa1. Recently, the study of these polymorphisms is becoming increas-
ingly popular because their detection can be a reliable diagnostic characteristic in 
determining the risk of T2D development. The association between VDR poly-
morphisms and abdominal obesity has shown that patients with Bsm1 and Apa1 
polymorphisms have low vitamin D status, which is accompanied by an increase 
in the concentrations of TC, LDL, and TG [69]. The results of another study show 
that body weight and BMI were significantly associated with polymorphisms Bsm1 
and Taq1, while Bsm1 strongly correlated with elevated HbA1c level. The frequency 
of the heterozygous genotype of the Bsm1 polymorphism was significantly greater 
in type 2 diabetics than in controls [70]. A study of this parameter in a group of 
patients with T2D from India revealed that it was Taq1 and Bsm1 polymorphisms 
that were closely associated with diabetes [71]. Thus, it can be concluded that the 
detection of different types of VDR gene polymorphisms is a reliable prognostic 
parameter for the risk of T2D. In addition, the type of polymorphism appears to be 
race-specific.
Despite a large amount of data on the association of CYP27B1 polymorphisms 
with the risk of T1D, the effect of different SNP variants of this gene in the develop-
ment of T2D is unclear to this day [72, 73].
While the closest relationship between VDR polymorphism in T2D has long 
been established, the discovery of the effect of CYP2R1 gene polymorphisms on 
the risk of developing this disease was a real step forward. Among a large group of 
tested SNPs of CYP2R1 gene, only two of them showed reliable association with the 
incidence of T2D. However, none of the tested polymorphisms were independently 
associated with serum 25OHD levels [74].
The effect of VD supplementation on glucose metabolism in patients with 
T2D remains controversial. It was shown that replenishing VD deficiency with 
high doses of cholecalciferol helped to reduce non-HDL cholesterol and caused 
significant normalizing changes in metabolic parameters of glucose homeostasis 
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(fasting glucose and serum insulin) and a decrease in oxidative stress and DNA 
damage [75, 76]. VD supplementation also caused an increase in insulin secretion 
and insulin sensitivity in T2D patients [77]. Nevertheless, some research groups 
did not find any effect, or only a slight decrease in fasting plasma glucose and an 
improvement in IR were seen. Basically, patients with VD deficiency and impaired 
glucose tolerance at baseline demonstrated these latter effects [68].
In addition to the ability of VD to reduce the risk of T2D, an adequate level of 
this vitamin in the body is also important for correcting diabetes-related pathologies 
such as retinopathy, nephropathy, neuropathy, and secondary osteoporosis caused 
by diabetes. Moreover, patients with already diagnosed T2D also have a risk of devel-
oping VD deficiency, in particular, due to the progression of nephropathy caused by 
diabetes [78]. Serum 25OHD was shown to be significantly reduced in patients with 
diabetic nephropathy [79]. Thus, the relationship between VD deficiency and the 
incidence of type 2 diabetes and related complications is likely to be bilateral.
Continuing the discussion on diabetic complications, we may note that vitamin 
D deficiency correlates with the risk of diabetic retinopathy. However, the reliable 
establishment of this relationship is problematic due to a number of limiting factors: 
cross-sectional structure, small sample size, ethnic variation, and heterogeneity in 
criteria that do not contribute to the identification of VD deficiency. Nevertheless, 
at least two state-of-the-art meta-analyses of observational studies indicate that D 
hypovitaminosis among T2D patients is associated with a significantly increased 
risk of diabetic retinopathy [80, 81].
A meta-analysis of data on the relationship between VD deficiency and the 
development of diabetes-induced neuropathy also revealed a strong correlation. 
Recovery of insulin secretion, increasing insulin sensitivity of target tissues, and 
reducing the inflammatory response have been proposed as potential mechanisms 
for improving the clinical manifestations of diabetic neuropathy following VD 
supplementation [82]. Furthermore, several independent studies have established 
serum 25OHD levels to predict cardiovascular complications or to assess the 
possible protective role of VD intake in patients with T2D. Diabetic patients with 
25OHD < 36 nmol/L manifested approximately 21% higher risk for developing 
macrovascular disease [83].
There is no doubt that achieving normal levels of 25OHD is an important factor 
in preventing the onset of T2D or for eliminating the complications associated with 
the disease. However, at the moment, the question of the VD dosage and duration of 
the complex therapy of patients with T2D remains unresolved. Based on interven-
tional trials, it can be postulated that the VD dose needs to be more than 2000 IU 
per day to raise blood 25OHD levels above 80 nmol/L, which is considered to be 
sufficient to reduce the risk of T2D [84]. However, the results of a double-blinded, 
placebo-controlled, randomized trial with 4000 IU of VD did not improve HbA1c 
or OGTT (oral glucose tolerance test)-based indices of β-cell function or insulin 
secretion in patients with stable T2D. The ambiguity of the results may be due to 
the following factors: the baseline 25OHD concentration was too high (<27 ng/mL), 
whereas a significant reduction in HbA1c and fasting glucose after VD supplemen-
tation was reported only among patients with baseline 25OHD < 20 ng/mL; VD may 
have no detectable effect in persons with well-controlled diabetes (good glycemic 
control, HbA1c-6.6%); and/or metformin treatment, which may have masked a 
small effect of VD supplementation [85]. These data indicate the need for indi-
vidual VD therapy for each patient with a risk of development or with an already 
established diagnosis of T2D. When choosing this type of therapy, it is necessary to 
take into account the initial level of 25OHD in the patient’s blood, changes in this 
level during therapy, as well as the presence of other drugs in the treatment regimen 




A two-way relationship between VD status and T1D and T2D can be argued. At 
the moment, it seems undeniable that there is a causal association between the risk 
of diabetes mellitus development and numerous polymorphisms in genes respon-
sible for metabolism (CYP2R1 and CYP27B1) and signaling (VDR) of VD. Despite 
the fact that diabetes mellitus is a multifactorial disease, and it is unlikely that 
VD deficiency is the main cause of this pathology, there is no doubt that it may 
be used in the complex treatment of diabetes mellitus and its complications. The 
importance of more comprehensive and randomized clinical trials to determine the 
therapeutic role of vitamin D in preventing the progression of glucose intolerance in 
groups at high risk of developing T2D should be noted.
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